Title of article :
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial
Author/Authors :
Tony W. Ho، نويسنده , , Michel D Ferrari، نويسنده , , David W Dodick، نويسنده , , Vince Galet، نويسنده , , James Kost، نويسنده , , Xiaoyin Fan، نويسنده , , Heather Leibensperger، نويسنده , , Samar Froman، نويسنده , , Christopher Assaid، نويسنده , , Christopher Lines، نويسنده , , Hille Koppen، نويسنده , , Paul K Winner، نويسنده ,
Abstract :
Summary
Background
Calcitonin gene-related peptide (CGRP) probably has a role in migraine pathophysiology, and antagonism of its receptors might provide treatment without the vasoconstrictor effects of triptans. We aimed to assess the clinical profile of
